Anti-RUNX1 / AML1 抗体 (ab23980)
Key features and details
- Rabbit polyclonal to RUNX1 / AML1
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-RUNX1 / AML1 antibody
RUNX1 / AML1 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to RUNX1 / AML1 -
由来種
Rabbit -
アプリケーション
適用あり: WBmore details -
種交差性
交差種: Human
交差が予測される動物種: Rat
-
免疫原
Synthetic peptide corresponding to Human RUNX1/ AML1 aa 200-300 conjugated to keyhole limpet haemocyanin.
(Peptide available asab24287) -
特記事項
Antibody batches of a concentration <1mg/ml will have BSA added to them.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA -
Concentration information loading... -
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
ChIP Related Products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab23980の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| WB | (6) |
Use a concentration of 1 µg/ml. Detects a band of approximately 52 kDa (predicted molecular weight: 48 kDa).
|
| 特記事項 |
|---|
|
WB
Use a concentration of 1 µg/ml. Detects a band of approximately 52 kDa (predicted molecular weight: 48 kDa). |
ターゲット情報
-
機能
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation. -
組織特異性
Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. -
関連疾患
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16. -
配列類似性
Contains 1 Runt domain. -
ドメイン
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes. -
翻訳後修飾
Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
Methylated. -
細胞内局在
Nucleus. - Information by UniProt
-
参照データベース
- Entrez Gene: 861 Human
- Entrez Gene: 50662 Rat
- Omim: 151385 Human
- SwissProt: Q01196 Human
- SwissProt: Q63046 Rat
- Unigene: 149261 Human
- Unigene: 612648 Human
- Unigene: 11201 Rat
-
別名
- Acute myeloid leukemia 1 antibody
- Acute myeloid leukemia 1 protein antibody
- alpha subunit core binding factor antibody
see all
画像
-
Western blot - Anti-RUNX1 / AML1 antibody (ab23980)Anti-RUNX1 / AML1 antibody (ab23980) at 1 µg/ml + Jurkat nuclear extract lysate (ab14844) at 20 µg
Secondary
Rabbit IgG secondary antibody (ab28446) at 1/10000 dilution
Predicted band size: 48 kDa
Observed band size: 48,52,55 kDa why is the actual band size different from the predicted?
This antibody recognized three distinct bands of between 48 and 55 kDa in Jurkat nuclear lysate. These may represent distinct isoforms of Runx1 or may represent post-translationally modified forms.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (152)
ab23980 は 152 報の論文で使用されています。
- Zhang X et al. Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma. Biomol Biomed 23:405-425 (2023). PubMed: 36321611
- Chambers C et al. SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer Res 83:983-996 (2023). PubMed: 36662812
- Pham D et al. Batf stabilizes Th17 cell development via impaired Stat5 recruitment of Ets1-Runx1 complexes. EMBO J 42:e109803 (2023). PubMed: 36917143
- She C et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress. J Exp Clin Cancer Res 42:238 (2023). PubMed: 37697370
- Wray JP et al. Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability. Nat Commun 13:7124 (2022). PubMed: 36411286